bear v2.0.1 (upwards) cont'd [🇷 for BE/BA]

posted by yjlee168 Homepage – Kaohsiung, Taiwan, 2008-10-28 09:59 (6076 d 23:09 ago) – Posting: # 2587
Views: 33,784

(edited on 2008-10-28 10:38)

dear EM,

Thank you for your message. No wonder that I cannot find anything about the method to analyze imbalanced sequence, BE data from US-FDA guideline. Yes, we've already been able to calculated Type I SS and Type III SS with bear right now. Thus, bear can analyze imbalanced or balanced sequence, BE data using lm method. In your message of previous thread, you said it might be "unsafe" if we used lm to analyze imbalanced BE data. And in the following replied message, you said it might be "unstable or incorrect" (from another forum) if we do so. Could you please give us more details about why you said so? What have you seen if one uses lm to analyze an imbalanced sequence BE? It sounds like lme or SAS PROC MIXED is preferred when analyzing imbalanced sequence BE. Am I correct?

All the best,
-- Yung-jin Lee
bear v2.9.2:- created by Hsin-ya Lee & Yung-jin Lee
Kaohsiung, Taiwan https://www.pkpd168.com/bear
Download link (updated) -> here

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,672 registered users;
34 visitors (0 registered, 34 guests [including 22 identified bots]).
Forum time: 10:08 CEST (Europe/Vienna)

Truth and clarity are complementary.    Niels Bohr

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5